Medicine reference
Dulaglutide
A source-linked medicine reference on Dulaglutide, its documented context and safety boundaries. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 March 2027.
Identity and scope
Dulaglutide is a prescription incretin-mimetic medicine. It is not a generic peptide supplement or a substitute for diabetes assessment.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Documented context
The cited monograph describes use to control blood glucose in certain people with type 2 diabetes. It does not make a broad longevity or appetite claim.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Safety and a useful record
The monograph includes a thyroid-tumour warning based on rat findings with uncertainty in humans and requires medicine and health-history review.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Record the prescribed product, indication, other glucose medicines, laboratory monitoring and adverse effects.
Published sources
- Dulaglutide injection
MedlinePlus / American Society of Health-System Pharmacists. Current ASHP consumer monograph; accessed 6 September 2026.
Supports: Type 2 diabetes use, warnings and medicine safety context.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.